Anti-obesity drug development

Expert Opinion on Investigational Drugs

Volumn 11, Issue 9, 2002, Pages 1189-1204

  Bays, Harold ^a   Dujovne, Carlos ^a  

^a RADIANT RESEARCH   (United States)

Author keywords

'Obesity metabolic cycle'; Anaesthesia; Appetite; Heart valve; Obesity; Obesity guideline; Resting metabolic rate; Satiety

Indexed keywords

AGOUTI RELATED PROTEIN; AMFEBUTAMONE; AMFEPRAMONE; ANOREXIGENIC AGENT; ANTIOBESITY AGENT; BENZPHETAMINE; BETA 3 ADRENERGIC RECEPTOR STIMULATING AGENT; BROMOCRIPTINE; CANNABINOID RECEPTOR ANTAGONIST; DEXAMPHETAMINE; DEXFENFLURAMINE; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE UPTAKE INHIBITOR; FENFLURAMINE; GLUCAGON LIKE PEPTIDE 1; MAZINDOL; METFORMIN; OCTREOTIDE; PHENDIMETRAZINE; PHENTERMINE; PRASTERONE; RECOMBINANT CILIARY NEUROTROPHIC FACTOR; RISPERIDONE; SEROTONIN 2C AGONIST; SIBUTRAMINE; SOMATOSTATIN DERIVATIVE; STEROID; TETRAHYDROLIPSTATIN; TOPIRAMATE; UNINDEXED DRUG;

ADULT; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DIET THERAPY; DISEASE COURSE; DRUG DESIGN; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; EPIDEMIC; FEMALE; HUMAN; HYPERTENSION; HYPERTHERMIA; HYPOGLYCEMIA; HYPOTENSION; INDUSTRIALIZATION; KINESIOTHERAPY; LIFESTYLE; METABOLIC DISORDER; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUTRITIONAL DISORDER; OBESITY; PUBLIC HEALTH; RAT; REVIEW; TACHYCARDIA; VALVULAR HEART DISEASE; WORLD HEALTH ORGANIZATION;

ANIMALS; ANTI-OBESITY AGENTS; HUMANS; OBESITY; TECHNOLOGY, PHARMACEUTICAL;

EID: 0036736491     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.11.9.1189     Document Type: Review

References (99)

1. The spread of the obesity epidemic in the United States
2. The Disease Burden Associated with Overweight and Obesity
3. Obesity: Preventing and managing the global epidemic
4. Pounds of prevention: Obesity therapy
5. Medical management of obesity
6. Medical management of obesity
7. The continuing epidemics of obesity and diabetes in the United States
8. Annual deaths attributable to obesity in the United States
9. Morbidity of severe obesity
10. The treatment of obesity in Type 2 diabetes mellitus
11. Successful management of the obese patient
12. Drug therapy for obesity
13. Pharmacotherapy for obesity
14. Obesity
15. Thermogenic effects of sibutramine and its metabolites
16. Long-term weight loss with sibutramine
17. Effect of sibutramine on weight maintenance after weight loss: A randomized trial
18. Effects of sibutramine on body weight and serum lipids
19. Sibutramine: A review of clinical efficacy
20. Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with Type 2 diabetes mellitus
21. Sibutramine is effective for weight loss and diabetic control in obesity with Type 2 diabetes: A randomized, double-blind, placebo controlled study
22. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat
23. Randomized placebo-controlled trial of orlistate for weight loss and prevention of weight regain in obest patients
24. Orlistat inhibits daily cholesterol absorption
25. Effects of weight loss with orlistat on glucose tolerance and progression to Type 2 diabetes in obese adults
26. The effect of orlistat on body weight and coronary heart disease risk profile in obest patients: The Swedish Multimorbidity Study
27. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity
28. Effects of dietary modification and treatment of obesity
29. Behavioral treatment of obesity
30. Axokine® causes significant weight loss in severely and morbidly obese subjects
31. Weight loss with Axokine® does not appear to be followed by rebound weight regain
32. Cannabis: Time for scientific evaluation of this ancient remedy?
33. Letter to the Editor: Risperidone in Prader-Willi Syndrome
34. Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications
35. Possible role of valvular serotonin 5-HT (2B) receptors in the cardiopathy associated with fenfluramine
36. Bupropion for weight loss: An investigation of efficacy and tolerability in overweight and obese women
37. Treatment of binge-eating disorder with topiramate: A clinical case series
38. Topiramate reduces energy and fat gains in lean(Fa/?) and Obese (fa/fa) Zucker Rats
39. Novel anti-obesity drugs
40. Antidepressant, anxiolytic and anorectic effects of a melanin-concentrating hormone - 1 receptor antagoinist
41. The role of NPY in metabolic homeostasis: Implications for obesity therapy
42. Association of beta 3 adrenoceptor polymorphism with obesity and diabetes: Current status
43. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice
44. Effect of triiodothyronine on mitochondrial energy coupling in human skeletal muscle
45. Recombinant leptin for weight loss in obese and lean adults
46. The neuroendocrinology of obesity
47. Editorial: Leptin as a therapeutic agent - Trials and tribulations
48. Weekly subcutaneous pegylated recombinant native human leptin (PEG-OB) administration in obese men
49. The effect of pegylated recombinant human leptin (PEG-OB) on weight loss and inflammatory status in obese subjects
50. Obesity, a modern day epidemic
51. Andidiabetogenic action of cholecystokinin-8 in Type 2 diabetes
52. A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans
53. Effect of 6-week course of glucagons-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in Type 2 diabetes: A parallel-group study
54. Action of glucagon and glucagon-like peptide
55. Assessing plasma lipid levels, body weight, and hepatic and renal toxicity following chronic oral administration of a water soluble phytostanol compound, FM-VP4, to gerbils
56. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery
57. Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without polycystic ovary syndrome
58. PPAR's: Nuclear receptors for antidiabetics
59. A proteome analysis of livers from obese (ob/ob) mice treated with the peroxisome proliferators WY 14,643
60. Nonhypoglycemic drug reactions of agents used to treat diabetes
61. Reversing adipocyte differentiation: Implications for treatment of obesity
62. PPAR gamma agonists and antagonists
63. Hypothalamic obesity caused by cranial insult in children: Altered glucose and insulin dynamics and reversal by a somatostatin agonist
64. Sustained benefit after 2 years of growth hormone on body composition, fat utilization, physical strength, and agility and growth in Prader-Willi syndrome
65. Is dehydroepiandrosterone an antiobesity agent?
66. A transgenic model of visceral obesity and the metabolic syndrome
67. Peripheral administration of human corticotropin-releasing hormone: A novel method to increase energy expenditure and fat oxidation in man
68. Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine: US Department of Health and Human Services Interim Public Health Recommendations
69. The appetite suppressant d-fenfluramine induces apoptosis in human serotonergic cells
70. The prevalence of cardiac valvular insufficiency assessed by transthorasic echocardiography in obese patients treated with appetite-suppressant drugs
71. Echocardiographic prevalence of mitral and/or aortic regurgitation in patients exposed to either fenfluramine-phentermine combination or to dexfenfluramine
72. A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation
73. Fenfluramine and phentermine and cardiovascular findings: Effect of treatment duration on prevalence of valve abnormalities
74. Dose-effect of fenfluramine use on the severity of valvular heart disease among fenphen patients with valvulopathy
75. Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (The Framingham Heart Study)
76. Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine/fenfluramine
77. Treatment with phentermine-fenfluramine was associated with a low prevalence of significant valvular heart disease
78. Clinical and echocardiographic follow-up of patients previously treated with dexfenfluramine or phentermine/fenfluramine
79. Anethetic considerations for the new antiobesity medications
80. Unusual hypotension and bradycardia in a patient receiving fenfluramine, phentermine, and fluoxetime
81. Current estimates of the economic cost of obesity in the United States
82. The effects of obesity, smoking, and problem drinking on chronic medical problems and health care costs
83. Does obesity contribute as much to morbidity as poverty or smoking?
84. Scientific and legal issues in fenfluramine/dexfenfluramine litigation
85. Bias, discrimination, and obesity
86. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
87. American College of Endocrinology Consensus Statement on Guidelines for Glycemic Control
88. Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure
89. The 1988 report of the Joint National Committee on the detection, evaluation and treatment of high blood pressure (JNC IV)
90. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance diabetes
91. Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
92. Adult Treatment Panel II. Summary of the Second Report of the National Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
93. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
94. The endocrinology of obesity
95. Prevalence of the metabolic syndrome among US adults
96. Unlike leptin, ciliary neurotrophic factor does not reverse the starvation-induced changes of serum corticosterone and hypothalamic neuropeptide levels but induces expression of hypothalamic inhibitors of leptin signaling
97. Obesity and heart failure- risk factor of mechanism?
98. Gut hormone PYY 3-36 physiologically inhibits food intake